Patient P-02648

Synthetic patientMETA-24 · Day 154 · 45–54 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 67 SC-12 recommended — Supportive Compound SC-12
Day 68 Patient accepted — Started SC-12 in the companion
Day 74 GI symptom burden −20% vs expected — Supportive Compound SC-12
Day 79 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 80 Tolerance state changed — Unstable → Improving
Day 85 ME-01 recommended — Monitoring Escalation ME-01
Day 86 Patient accepted — Started ME-01 in the companion
Day 89 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 79.

Primary contributors, last 14 days

Nutritional resilience-14
Treatment adherence+13
GI instability+10
Inflammatory activity+7
Toxicity+3

What helped?

Supportive Compound SC-12Day 67
Result: symptom burden −20%
Monitoring Escalation ME-01Day 85
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
86% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

44 min

stable · -0.4 vs previous 14 d

Sleep duration

Wearable

5.8 h

stable · -0.2 vs previous 14 d

Energy level

Daily log

1.8/10

worsening · -0.4 vs previous 14 d

Steps

Wearable

5,078

worsening · -293 vs previous 14 d

GI burden

Companion

64.2/100

worsening · +5.4 vs previous 14 d

Adherence

Companion

52.8 %

stable · +0.2 vs previous 14 d

Sleep quality

Wearable

16/100

worsening · -2.3 vs previous 14 d

Glucose, CGM daily mean

CGM

153 mg/dL

stable · +1.9 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 24 from the failing basin, 68 from restoration.

Would help

GI-04 GI Support Protocol
74% improved among 66 similar · onset 8 d · confidence 97%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 80%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 80%
More protein
GI -4 next day on high-intake days · n 18

Would not help

Keep fat low
GI +4.6 next day on high-intake days · n 23
Keep histamine low
GI +4.3 next day on high-intake days · n 21
Keep ultra-processed low
GI +3.3 next day on high-intake days · n 16

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+4.6detractor · 95%
Histamine load
+4.3detractor · 95%
Protein
-4supporter · 95%
Ultra-processed food
+3.3detractor · 90%
Alcohol
+3.1detractor · 93%
Simple carbohydrates
+2.4detractor · 73%
Caffeine
+0.6no signal · 15%
Insoluble fibre
+0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 64 and rising
- WearableSleep 5.8 h, below personal baseline
Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 62
- WearableHRV 21 ms, trending down
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 26/100
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓45
- WearableResting HR 84 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 56

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Intermediate metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2.1 · butyrate capacity 26/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 26 ms
Sleep: 6.5 h
Steps: 5,294
Resting HR: 83 bpm

Daily log: GI score 64, nutritional resilience 29, adherence 53.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02018	46%	S01	GI-04	improved	46
P-02409	35%	S01	SC-12	no change	54
P-02410	35%	S01	GI-04	improved	55
P-02054	33%	S01	CR-01	improved	57
P-02307	21%	S01	—	—	55
P-02598	21%	S01	—	—	53
P-02041	20%	S01	—	—	27
P-02276	20%	S01	—	—	57
P-02550	20%	S01	—	—	70
P-02087	19%	S01	BR-03	no change	40
P-02437	19%	S01	—	—	64
P-02568	19%	S01	—	—	51